Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Testing a Claim about Population Proportion01:24

Testing a Claim about Population Proportion

A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
Statistical Methods to Analyze Parametric Data: Student t-Test and Goodness-of-Fit Test01:09

Statistical Methods to Analyze Parametric Data: Student t-Test and Goodness-of-Fit Test

In parametric statistics, two fundamental tests stand out for their utility and wide application: the Student's t-test and goodness-of-fit tests. These tests provide researchers with a robust method for drawing insights from data, testing hypotheses, and making informed decisions based on their findings.
The Student's t-test is a statistical test that examines if there is a statistically significant difference between the means of two groups. This test is instrumental when dealing with data...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Select Contemporary Statistical Concepts in Heart Failure Clinical Trials: Insights From the Heart Failure Collaboratory.

JACC. Heart failure·2026
Same author

Rejoinder to Commentaries on "A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events".

Statistics in medicine·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Clinical trials for continuously monitored and updated AI systems.

Nature medicine·2026
Same author

Reflections on FDA Draft Guidance on Bayesian Methods in Trials-Protecting Scientific Integrity and Evidentiary Standards.

JAMA·2026

Related Experiment Video

Updated: May 21, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Testing in a Prespecified Subgroup and the Intent-to-Treat Population.

Mark D Rothmann1, Jenny J Zhang, Laura Lu

  • 1Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

Drug Information Journal
|June 23, 2012
PubMed
Summary

Biomarker subgroup analysis in clinical trials requires careful consideration. Including biomarker-negative patients in primary analyses can lead to logically inconsistent and potentially misleading treatment effect conclusions.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: May 21, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmacogenomics

Background:

  • Biomarker subgroup analyses are common in clinical trials to identify patient groups with differential treatment effects.
  • Experimental regimens may show stronger efficacy in biomarker-positive subgroups due to biological plausibility.
  • Including biomarker-negative patients in overall analyses can obscure true treatment effects.

Purpose of the Study:

  • To examine the statistical and logical implications of including biomarker-negative patients in clinical trial analyses.
  • To address the complexities of subgroup claims based on biomarker status.
  • To highlight inconsistencies in trial designs that analyze both biomarker-positive and biomarker-negative groups.

Main Methods:

  • Review of statistical principles for subgroup analysis in clinical trials.
  • Logical assessment of treatment effect claims in biomarker-defined populations.
  • Examination of prespecified analysis plans and their implications.

Main Results:

  • A statistically significant result in biomarker-positive subgroups supports a claim for that specific group.
  • Overall population claims including biomarker-negative patients are problematic if these patients do not benefit.
  • Including biomarker-positive patients in the analysis for biomarker-negative patients is logically inconsistent when differential effects are expected.

Conclusions:

  • Careful prespecification of subgroup analyses is crucial to avoid logical inconsistencies.
  • Biomarker status must be rigorously considered when defining patient populations for treatment effect claims.
  • Trial designs should clearly delineate analyses for biomarker-positive and biomarker-negative subgroups to ensure valid conclusions.